B Cells and Transplantation: An Educational Resource

Biology of Blood and Marrow Transplantation

Volumn 15, Issue 1 SUPPL., 2009, Pages 104-113

  Small, Trudy N ^a   Robinson, William H ^b   Miklos, David B ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE ANTIBODY; CHICKENPOX VACCINE; HEPATITIS B VACCINE; IMATINIB; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLUENZA VACCINE; MEASLES MUMPS RUBELLA VACCINE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PNEUMOCOCCUS VACCINE; POLIOMYELITIS VACCINE; POLYSACCHARIDE VACCINE; PROTEIN TYROSINE KINASE INHIBITOR; RITUXIMAB; STEROID; TETANUS TOXOID; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBODY PRODUCTION; ANTIGEN ANTIBODY REACTION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; BLOOD TOXICITY; CELL MATURATION; CELL SURVIVAL; CELLULAR IMMUNITY; CHICKENPOX; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; GLYCOSYLATION; HEPATITIS B; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; INFECTION; INFLUENZA; MEASLES; MORTALITY; MUMPS; MYELOABLATIVE CONDITIONING; NONHUMAN; ONTOGENY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PNEUMOCOCCAL INFECTION; POLIOMYELITIS; RUBELLA; SYSTEMIC SCLEROSIS;

EID: 64749113867     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2008.10.016     Document Type: Article

References (115)

1. van Tol M.J., Gerritsen E.J., de Lange G.G., et al. The origin of IgG production and homogeneous IgG components after allogeneic bone marrow transplantation. Blood 87 (1996) 818-826
2. Wimperis J.Z., Brenner M.K., Prentice H.G., Thompson E.J., and Hoffbrand A.V. B cell development and regulation after T cell-depleted marrow transplantation. J Immunol 138 (1987) 2445-2450
3. Petersdorf E.W., Hansen J.A., Martin P.J., et al. Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation. N Engl J Med 345 (2001) 1794-1800
4. Taylor P.A., Ehrhardt M.J., Roforth M.M., et al. Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients. Blood 109 (2007) 1307-1315
5. Bolan C.D., Leitman S.F., Griffith L.M., et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood 98 (2001) 1687-1694
6. Griffith L.M., McCoy Jr. J.P., Bolan C.D., et al. Persistence of recipient plasma cells and anti-donor isohaemagglutinins in patients with delayed donor erythropoiesis after major ABO incompatible non-myeloablative haematopoietic cell transplantation. Br J Haematol 128 (2005) 668-675
7. Brown V.I., Hulitt J., Fish J., et al. Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling. Cancer Res 67 (2007) 9963-9970
8. Dai X., Chen Y., Di L., et al. Stat5 is essential for early B cell development but not for B cell maturation and function. J Immunol 179 (2007) 1068-1079
9. Kalis S.L., Zhai S.K., Yam P.C., Witte P.L., and Knight K.L. Suppression of B lymphopoiesis at a lymphoid progenitor stage in adult rabbits. Int Immunol 19 (2007) 801-811
10. Koralov S.B., Muljo S.A., Galler G.R., et al. Dicer ablation affects antibody diversity and cell survival in the B lymphocyte lineage. Cell 132 (2008) 860-874
11. Meffre E., and Nussenzweig M.C. Deletion of immunoglobulin beta in developing B cells leads to cell death. Proc Natl Acad Sci USA 99 (2002) 11334-11339
12. Pfeifhofer C., Gruber T., Letschka T., et al. Defective IgG2a/2b class switching in PKC alpha-/- mice. J Immunol 176 (2006) 6004-6011
13. Sasaki Y., Casola S., Kutok J.L., Rajewsky K., and Schmidt-Supprian M. TNF family member B cell-activating factor (BAFF) receptor-dependent and -independent roles for BAFF in B cell physiology. J Immunol 173 (2004) 2245-2252
14. Calame K.L. Mechanisms that regulate immunoglobulin gene expression. Annu Rev Immunol 3 (1985) 159-195
15. Calame K.L., Lin K.I., and Tunyaplin C. Regulatory mechanisms that determine the development and function of plasma cells. Annu Rev Immunol 21 (2003) 205-230
16. Cyster J.G., Hartley S.B., and Goodnow C.C. Competition for follicular niches excludes self-reactive cells from the recirculating B-cell repertoire. Nature 371 (1994) 389-395
17. Gorelik L., Gilbride K., Dobles M., Kalled S.L., Zandman D., and Scott M.L. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med 198 (2003) 937-945
18. Miller J.P., Stadanlick J.E., and Cancro M.P. Space, selection, and surveillance: setting boundaries with BLyS. J Immunol 176 (2006) 6405-6410
19. Thien M., Phan T.G., Gardam S., et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 20 (2004) 785-798
20. Cancro M.P. Living in context with the survival factor BAFF. Immunity 28 (2008) 300-301
21. De Falco M., Oliva G., Ragusa M., et al. Surgical treatment of differentiated thyroid carcinoma: a retrospective study. G Chir 29 (2008) 152-158
22. Sarantopoulos S., Stevenson K.E., Kim H.T., et al. High levels of B-cell activating factor in patients with active chronic graft-versus-host disease. Clin Cancer Res 13 (2007) 6107-6114
23. Gross J.A., Johnston J., Mudri S., et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404 (2000) 995-999
24. Mackay F., and Browning J.L. BAFF: a fundamental survival factor for B cells. Nat Rev Immunol 2 (2002) 465-475
25. Mariette X., Roux S., Zhang J., et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 62 (2003) 168-171
26. Halterman R.H., Graw Jr. R.G., Fuccillo D.A., and Leventhal B.G. Immunocompetence following allogeneic bone marrow transplantation in man. Transplantation 14 (1972) 689-697
27. Fass L., Ochs H.D., Thomas E.D., Mickelson E., Storb R., and Fefer A. Studies of immunological reactivity following syngeneic or allogeneic marrow grafts in man. Transplantation 16 (1973) 630-640
28. Asma G.E., van den Bergh R.L., and Vossen J.M. Regeneration of TdT+, pre-B, and B cells in bone marrow after allogeneic bone marrow transplantation. Transplantation 43 (1987) 865-870
29. Small T.N., Keever C.A., Weiner-Fedus S., Heller G., O'Reilly R.J., and Flomenberg N. B-cell differentiation following autologous, conventional, or T-cell depleted bone marrow transplantation: a recapitulation of normal B-cell ontogeny. Blood 76 (1990) 1647-1656
30. Leitenberg D., Rappeport J.M., and Smith B.R. B-cell precursor bone marrow reconstitution after bone marrow transplantation. Am J Clin Pathol 102 (1994) 231-236
31. Witherspoon R.P., Storb R., Ochs H.D., et al. Recovery of antibody production in human allogeneic marrow graft recipients: influence of time posttransplantation, the presence or absence of chronic graft-versus-host disease, and antithymocyte globulin treatment. Blood 58 (1981) 360-368
32. Gerritsen E.J., van Tol M.J., Lankester A.C., et al. Immunoglobulin levels and monoclonal gammopathies in children after bone marrow transplantation. Blood 82 (1993) 3493-3502
33. Mitus A.J., Stein R., Rappeport J.M., et al. Monoclonal and oligoclonal gammopathy after bone marrow transplantation. Blood 74 (1989) 2764-2768
34. Raaphorst F.M. Reconstitution of the B cell repertoire after bone marrow transplantation does not recapitulate human fetal development. Bone Marrow Transplant 24 (1999) 1267-1272
35. Suzuki I., Milner E.C., Glas A.M., et al. Immunoglobulin heavy chain variable region gene usage in bone marrow transplant recipients: lack of somatic mutation indicates a maturational arrest. Blood 87 (1996) 1873-1880
36. Gokmen E., Raaphorst F.M., Boldt D.H., and Teale J.M. Ig heavy chain third complementarity determining regions (H CDR3s) after stem cell transplantation do not resemble the developing human fetal H CDR3s in size distribution and Ig gene utilization. Blood 92 (1998) 2802-2814
37. Nasman I., and Lundkvist I. Evidence for oligoclonal diversification of the VH6-containing immunoglobulin repertoire during reconstitution after bone marrow transplantation. Blood 87 (1996) 2795-2804
38. Nasman-Bjork I., and Lundkvist I. Oligoclonal dominance of immunoglobulin VH3 rearrangements following allogeneic bone marrow transplantation. Bone Marrow Transplant 21 (1998) 1223-1230
39. Wimperis J.Z., Berry N.J., Brenner M.K., et al. Production of anti-cytomegalovirus antibody following T-cell depleted bone marrow transplant. Br J Haematol 63 (1986) 659-664
40. Brenner M.K., Wimperis J.Z., Reittie J.E., et al. Recovery of immunoglobulin isotypes following T-cell depleted allogeneic bone marrow transplantation. Br J Haematol 64 (1986) 125-132
41. Wimperis J.Z., Berry N.J., Prentice H.G., Lever A., Griffiths P.D., and Brenner M.K. Regeneration of humoral immunity to herpes simplex virus following T-cell-depleted allogeneic bone marrow transplantation. J Med Virol 23 (1987) 93-99
42. Wimperis J.Z., Brenner M.K., Prentice H.G., et al. Transfer of a functioning humoral immune system in transplantation of T-lymphocyte-depleted bone marrow. Lancet 1 (1986) 339-343
43. Wimperis J.Z., Gottlieb D., Duncombe A.S., Heslop H.E., Prentice H.G., and Brenner M.K. Requirements for the adoptive transfer of antibody responses to a priming antigen in man. J Immunol 144 (1990) 541-547
44. Steinberg A.G., and Cook C.E. The Distribution of Human Immunoglobin Allotype (1981), Oxford university Press, Oxford
45. Witherspoon R.P., Schanfield M.S., Storb R., Thomas E.D., and Giblett E.R. Immunoglobulin production of donor origin after marrow transplantation for acute leukemia or aplastic anemia. Transplantation 26 (1978) 407-408
46. Boiko J, Sahaf B, Mueller A, Chen G, Tyan D, Miklos D. IgG allotypes identify long-lived recipient plasma-cell responses after reduced-intensity hematopoietic cell transplantation. Abstract #349. American Society of Hematology 2008 Meeting. San Francisco, CA.
47. Storek J., Viganego F., Dawson M.A., et al. Factors affecting antibody levels after allogeneic hematopoietic cell transplantation. Blood 101 (2003) 3319-3324
48. Chen C.S., Boeckh M., Seidel K., et al. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation. Bone Marrow Transplant 32 (2003) 515-522
49. Machado C.M., Cardoso M.R., da Rocha I.F., Boas L.S., Dulley F.L., and Pannuti C.S. The benefit of influenza vaccination after bone marrow transplantation. Bone Marrow Transplant 36 (2005) 897-900
50. Koc Y., Miller K.B., Schenkein D.P., et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 6 (2000) 44-49
51. Ljungman P., Engelhard D., de la Camara R., et al. Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 35 (2005) 737-746
52. Machado C.M. Reimmunization after hematopoietic stem cell transplantation. Expert Rev Vaccines 4 (2005) 219-228
53. Parkkali T., Ruutu T., Stenvik M., et al. Loss of protective immunity to polio, diphtheria and Haemophilus influenzae type b after allogeneic bone marrow transplantation. APMIS 104 (1996) 383-388
54. Ljungman P., Aschan J., Barkholt L., et al. Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus host disease. Bone Marrow Transplant 34 (2004) 589-593
55. Ljungman P., Duraj V., and Magnius L. Response to immunization against polio after allogeneic marrow transplantation. Bone Marrow Transplant 7 (1991) 89-93
56. Jaffe D., Papadopoulos E.B., Young J.W., et al. Immunogenicity of recombinant hepatitis B vaccine (rHBV) in recipients of unrelated or related allogeneic hematopoietic cell (HC) transplants. Blood 108 (2006) 2470-2475
57. CDC. CDC. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR Morb Mortal Wkly Rep 49 RR-10 (2000) 1-125
58. EBMT: Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT P Ljungman1, D Engelhard1, R de la Cmara1, H Einsele1, A Locasciulli1, R Martino1, P Ribaud1, K Ward1 and C Cordonnier1 for the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation.
59. Barra A., Cordonnier C., Preziosi M.P., et al. Immunogenicity of Haemophilus influenzae type b conjugate vaccine in allogeneic bone marrow recipients. J Infect Dis 166 (1992) 1021-1028
60. Guinan E.C., Molrine D.C., Antin J.H., et al. Polysaccharide conjugate vaccine responses in bone marrow transplant patients. Transplantation 57 (1994) 677-684
61. Pao M., Papadopoulos E., Kernan N., Jakubowski A., Young J., and Castro-Malaspina H. Immunogenicity of haemophilus influenza and pneumococcal vaccines in related and unrelated transplant recipients. Blood 108 (2006) 178a
62. Storek J., Dawson M.A., Lim L.C., et al. Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation. Bone Marrow Transplant 33 (2004) 337-346
63. Avanzini M.A., Locatelli F., Dos Santos C., et al. B lymphocyte reconstitution after hematopoietic stem cell transplantation: functional immaturity and slow recovery of memory CD27+ B cells. Exp Hematol 33 (2005) 480-486
64. Lausen B.F., Hougs L., Schejbel L., Heilmann C., and Barington T. Human memory B cells transferred by allogenic bone marrow transplantation contribute significantly to the antibody repertoire of the recipient. J Immunol 172 (2004) 3305-3318
65. Molrine D.C., Guinan E.C., Antin J.H., et al. Donor immunization with Haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation. Blood 87 (1996) 3012-3018
66. Molrine D.C., Antin J.H., Guinan E.C., et al. Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation. Blood 101 (2003) 831-836
67. Meisel R., Kuypers L., Dirksen U., et al. Pneumococcal conjugate vaccine provides early protective antibody responses in children after related and unrelated allogeneic hematopoietic stem cell transplantation. Blood 109 (2007) 2322-2326
68. Pao M., Papadopoulos E.B., Chou J., et al. Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT). Biol Blood Marrow Transplant 14 (2008) 1022-1030
69. Machado C.M. Reimmunization after bone marrow transplantation-current recommendations and perspectives. Braz J Med Biol Res 37 (2004) 151-158
70. Storek J., Wells D., Dawson M.A., Storer B., and Maloney D.G. Factors influencing B lymphopoiesis after allogeneic hematopoietic cell transplantation. Blood 98 (2001) 489-491
71. Sanz I., Wei C., Lee F.E., and Anolik J. Phenotypic and functional heterogeneity of human memory B cells. Semin Immunol 20 (2008) 67-82
72. Avery D.T., Ellyard J.I., Mackay F., Corcoran L.M., Hodgkin P.D., and Tangye S.G. Increased expression of CD27 on activated human memory B cells correlates with their commitment to the plasma cell lineage. J Immunol 174 (2005) 4034-4042
73. Cappione III A., Anolik J.H., Pugh-Bernard A., et al. Germinal center exclusion of autoreactive B cells is defective in human systemic lupus erythematosus. J Clin Invest 115 (2005) 3205-3216
74. Odendahl M., Jacobi A., Hansen A., et al. Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol 165 (2000) 5970-5979
75. Arce E., Jackson D.G., Gill M.A., Bennett L.B., Banchereau J., and Pascual V. Increased frequency of pre-germinal center B cells and plasma cell precursors in the blood of children with systemic lupus erythematosus. J Immunol 167 (2001) 2361-2369
76. Sarantopoulos S., Stevenson K., Kim H.T., et al. Chronic GVHD is associated with a BAFF driven BCR-activated B cell repertoire. Blood (2007) 166
77. Siracusa L.D., McGrath R., Ma Q., et al. A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 6 (1996) 300-313
78. Phelps R.G., Daian C., Shibata S., Fleischmajer R., and Bona C.A. Induction of skin fibrosis and autoantibodies by infusion of immunocompetent cells from tight skin mice into C57BL/6 Pa/Pa mice. J Autoimmun 6 (1993) 701-718
79. Wallace V.A., Kondo S., Kono T., et al. A role for CD4+ T cells in the pathogenesis of skin fibrosis in tight skin mice. Eur J Immunol 24 (1994) 1463-1466
80. Hasegawa M., Hamaguchi Y., Yanaba K., et al. B-lymphocyte depletion reduces skin fibrosis and autoimmunity in the tight-skin mouse model for systemic sclerosis. Am J Pathol 169 (2006) 954-966
81. Schultz K.R., Paquet J., Bader S., and HayGlass K.T. Requirement for B cells in T cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 16 (1995) 289-295
82. Zhang C., Todorov I., Zhang Z., et al. Donor CD4+ T and B cells in transplants induce chronic graft versus host disease with autoimmune manifestations. Blood 107 (2006) 2993-3001
83. Perruche S., Kleinclauss F., Tiberghien P., and Saas P. B Cell allogeneic responses after hematopoietic cell transplantation: is it time to address this issue?. Transplantation 79 (2005) S37-S39
84. Miklos D.B., Kim H.T., Zorn E., et al. Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood 103 (2004) 353-359
85. Miklos D.B., Kim H.T., Miller K.H., et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft versus host disease and disease remission. Blood 105 (2005) 2973-2978
86. Stohl W., Metyas S., Tan S.M., et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 48 (2003) 3475-3486
87. Matsushita T., Hasegawa M., Yanaba K., Kodera M., Takehara K., and Sato S. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum 54 (2006) 192-201
88. Benson M.J., Erickson L.D., Gleeson M.W., and Noelle R.J. Affinity of antigen encounter and other early B-cell signals determine B-cell fate. Curr Opin Immunol 19 (2007) 275-280
89. Casola S., Otipoby K.L., Alimzhanov M., et al. B cell receptor signal strength determines B cell fate. Nat Immunol 5 (2004) 317-327
90. Stadanlick J.E., and Cancro M.P. BAFF and the plasticity of peripheral B cell tolerance. Curr Opin Immunol 20 (2008) 158-161
91. Harless S.M., Lentz V.M., Sah A.P., et al. Competition for BLyS-mediated signaling through Bcmd/BR3 regulates peripheral B lymphocyte numbers. Curr Biol 11 (2001) 1986-1989
92. Hsu B.L., Harless S.M., Lindsley R.C., Hilbert D.M., and Cancro M.P. Cutting edge: BLyS enables survival of transitional and mature B cells through distinct mediators. J Immunol 168 (2002) 5993-5996
93. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-vs.-host disease. Blood 108 (2006) 756-762
94. Zaja F., Bacigalupo A., Patriarca F., et al. Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant 40 (2007) 273-277
95. Mohty M., Marchetti N., El-Cheikh J., Faucher C., Furst S., and Blaise D. Rituximab as salvage therapy for refractory chronic GVHD. Bone Marrow Transplant 41 (2008) 909-911
96. Withers D.R., Fiorini C., Fischer R.T., Ettinger R., Lipsky P.E., and Grammer A.C. T cell-dependent survival of CD20+ and CD20- plasma cells in human secondary lymphoid tissue. Blood 109 (2007) 4856-4864
97. Sahaf B., Chen G., Boiko J., Heydari K., Arai S., and Miklos D. Rituximab Infusion after Allogeneic HCT Prevents Donor B Cell Reconstitution and Alloimmunity 1 Year Post Transplant (2008), American Society of Blood and Marrow Transplantaion, San Diego, Ca
98. Harris M.L., and Rosen A. Autoimmunity in scleroderma: the origin, pathogenetic role, and clinical significance of autoantibodies. Curr Opin Rheumatol 15 (2003) 778-784
99. Cepeda E.J., and Reveille J.D. Autoantibodies in systemic sclerosis and fibrosing syndromes: clinical indications and relevance. Curr Opin Rheumatol 16 (2004) 723-732
100. Ahmed S.S., Tan F.K., Arnett F.C., Jin L., and Geng Y.J. Induction of apoptosis and fibrillin 1 expression in human dermal endothelial cells by scleroderma sera containing anti-endothelial cell antibodies. Arthritis Rheum 54 (2006) 2250-2262
101. Sato S., Hayakawa I., Hasegawa M., Fujimoto M., and Takehara K. Function blocking autoantibodies against matrix metalloproteinase-1 in patients with systemic sclerosis. J Invest Dermatol 120 (2003) 542-547
102. Nishijima C., Hayakawa I., Matsushita T., et al. Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clin Exp Immunol 138 (2004) 357-363
103. Tan F.K., Arnett F.C., Reveille J.D., et al. Autoantibodies to fibrillin 1 in systemic sclerosis: ethnic differences in antigen recognition and lack of correlation with specific clinical features or HLA alleles. Arthritis Rheum 43 (2000) 2464-2471
104. Arnett F.C. Is scleroderma an autoantibody mediated disease?. Curr Opin Rheumatol 18 (2006) 579-581
105. Ferrara J.L., and Deeg H.J. Graft-versus-host disease. N Engl J Med 324 (1991) 667-674
106. Shulman H.M., Sullivan K.M., Weiden P.L., et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 69 (1980) 204-217
107. Wechalekar A., Cranfield T., Sinclair D., and Ganzckowski M. Occurrence of autoantibodies in chronic graft vs. host disease after allogeneic stem cell transplantation. Clin Lab Haematol 27 (2005) 247-249
108. Quaranta S., Shulman H., Ahmed A., et al. Autoantibodies in human chronic graft-versus-host disease after hematopoietic cell transplantation. Clin Immunol 91 (1999) 106-116
109. Chizzolini C., Raschi E., Rezzonico R., et al. Autoantibodies to fibroblasts induce a proadhesive and proinflammatory fibroblast phenotype in patients with systemic sclerosis. Arthritis Rheum 46 (2002) 1602-1613
110. Ludwicka A., Ohba T., Trojanowska M., et al. Elevated levels of platelet derived growth factor and transforming growth factor-beta 1 in bronchoalveolar lavage fluid from patients with scleroderma. J Rheumatol 22 (1995) 1876-1883
111. Baroni S.S., Santillo M., Bevilacqua F., et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 354 (2006) 2667-2676
112. Svegliati S., Olivieri A., Campelli N., et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 110 (2007) 237-241
113. Sambo P., Baroni S.S., Luchetti M., et al. Oxidative stress in scleroderma: maintenance of scleroderma fibroblast phenotype by the constitutive up-regulation of reactive oxygen species generation through the NADPH oxidase complex pathway. Arthritis Rheum 44 (2001) 2653-2664
114. Olivieri A., Locatelli F., Sanna R., Raimondi R., and Bacigalupo A. Imatinib for the treatment of advanced refractory chronic GvHD (2008), European Group for Blood and Marrow Transplantation Meeting, Florence, Italy
115. Panse J.P., Heimfeld S., Guthrie K.A., et al. Allogeneic peripheral blood stem cell graft composition affects early T-cell chimaerism and later clinical outcomes after non-myeloablative conditioning. Br J Haematol 128 (2005) 659-667